Global Antimicrobial Resistance Governance Assessment: Implications for Healthcare Policy Implementation and Clinical Practice

Abstract

Antimicrobial resistance (AMR) represents a critical threat to global health security, with an estimated 4.71 million deaths attributed to resistant infections in 2021. A comprehensive evaluation of national action plan (NAP) effectiveness across 193 countries between 2017-2022 utilized a multidimensional One Health governance index developed through structured Delphi expert consultation. The analysis integrated 269 policy documents with multinational surveillance datasets, employing difference-in-differences and joinpoint regression methodologies. Global governance scores demonstrated improvement from 30.7 to 44.5 per 100 points, though implementation and monitoring capabilities lagged substantially behind policy formulation, particularly within animal and environmental health sectors. Statistical analysis revealed significant increases in AMR prevalence scores occurring only five years post-NAP adoption (β = 2.43, 95% confidence interval 1.02-3.85, P < 0.05), emphasizing the temporal delay between policy implementation and measurable outcomes. Multisector engagement (β = 0.05, 95% CI 0.02-0.08, P < 0.01) and antimicrobial use surveillance systems (β = 0.05, 95% CI 0.03-0.07, P < 0.01) demonstrated the strongest associations with improved AMR outcomes among early-adopting nations. These findings provide critical evidence for healthcare administrators and infectious disease specialists regarding the temporal dynamics and essential components of effective AMR governance structures.

Introduction

Antimicrobial resistance constitutes one of the most pressing challenges in contemporary healthcare, fundamentally altering the landscape of infectious disease management across all medical specialties. The epidemiological burden continues to escalate, with current projections indicating potential increases in AMR-attributable mortality to 8.22 million deaths annually by 2050, accompanied by economic losses approaching 3.8% of global gross domestic product and potentially displacing 28 million individuals into extreme poverty.

The complexity of AMR as a clinical phenomenon extends beyond traditional healthcare boundaries, necessitating coordinated responses across human medicine, veterinary practice, agricultural systems, and environmental health sectors. This multifaceted nature prompted the 68th World Health Assembly to formally adopt the Global Action Plan on Antimicrobial Resistance in 2015, establishing a framework for national-level policy implementation through One Health principles.

The clinical implications of AMR governance extend directly into hospital-based practice, where infectious disease specialists, clinical microbiologists, and hospital epidemiologists confront increasing rates of multidrug-resistant organisms. Healthcare systems in Hawaii, including institutions such as The Queen’s Medical Center and Tripler Army Medical Center, face unique challenges in AMR management due to geographic isolation, diverse patient populations including Pacific Islander communities, and complex referral patterns across the Pacific Basin.

Despite widespread adoption of national action plans globally, the effectiveness of these governance structures in producing measurable clinical outcomes remains incompletely characterized. Previous assessments have focused predominantly on policy formulation rather than implementation effectiveness, creating a substantial knowledge gap regarding which specific governance components translate into improved patient outcomes and reduced resistance rates.

Study Design and Methods

The investigation employed a comprehensive mixed-methods approach to evaluate AMR governance effectiveness across all 193 United Nations member countries during the period 2017-2022. The research team developed a novel multidimensional One Health governance index through structured Delphi expert consultation methodology, incorporating input from specialists in infectious diseases, veterinary medicine, public health policy, and environmental health.

The governance assessment integrated multiple data sources, including 269 national policy documents, expert-weighted indicators derived from the Delphi consultation process, and multinational survey datasets. Surveillance data were obtained from established monitoring systems, including the World Health Organization Global Antimicrobial Resistance and Use Surveillance System (GLASS), the Food and Agriculture Organization’s monitoring framework, and national reporting mechanisms.

Statistical analysis utilized difference-in-differences methodology to establish causal relationships between governance implementation and AMR outcomes, accounting for temporal variations and country-specific baseline characteristics. Joinpoint regression analysis was employed to identify inflection points in resistance trends relative to policy implementation timelines. The analytical framework specifically examined the temporal relationship between NAP adoption and measurable changes in antimicrobial use patterns, AMR prevalence, and resistance-related mortality.

Primary endpoints included composite AMR prevalence scores derived from surveillance data for key pathogen-antimicrobial combinations. Secondary endpoints encompassed antimicrobial consumption metrics across human and veterinary sectors, policy implementation scores across One Health domains, and mortality attributable to resistant infections where data availability permitted robust analysis.

The governance index incorporated weighted assessments of policy design quality, implementation capacity, multisector coordination mechanisms, surveillance infrastructure, and monitoring capabilities. Expert weighting reflected the relative importance of different governance components based on available evidence and professional consensus regarding clinical impact potential.

Results

The global assessment revealed substantial heterogeneity in AMR governance capacity, with overall governance scores improving from 30.7 to 44.5 per 100 points during the study period. This improvement pattern demonstrated marked variation across different governance domains, with policy design components showing more rapid advancement than implementation and monitoring capabilities.

Particularly notable disparities emerged between human health sector governance and corresponding capabilities in animal and environmental health domains. Human health governance components achieved mean scores of 52.3 per 100 points by 2022, while animal health governance reached 41.7 per 100 points, and environmental health governance lagged at 29.8 per 100 points.

The temporal analysis revealed a critical finding regarding the delayed impact of policy implementation on measurable AMR outcomes. Statistical analysis demonstrated that significant increases in AMR prevalence scores occurred only five years after NAP adoption, with two-stage difference-in-differences analysis yielding a coefficient of 2.43 (95% confidence interval 1.02-3.85, P < 0.05). This temporal delay has profound implications for policy evaluation methodologies and healthcare planning processes.

Countries classified as early adopters of comprehensive governance frameworks demonstrated superior outcomes across multiple metrics. Multisector engagement emerged as the strongest predictor of favorable AMR outcomes, with early-adopting countries showing a coefficient of 0.05 (95% CI 0.02-0.08, P < 0.01) for this governance component. Similarly, antimicrobial use surveillance systems demonstrated comparable predictive value, with early-adopting countries achieving a coefficient of 0.05 (95% CI 0.03-0.07, P < 0.01).

The analysis identified specific governance components most strongly associated with improved clinical outcomes. Countries with robust multisector coordination mechanisms, particularly those incorporating veterinary and environmental health perspectives into human health decision-making processes, demonstrated more substantial reductions in resistance rates for priority pathogens.

Surveillance system characteristics proved critical in determining governance effectiveness. Countries implementing integrated surveillance platforms capable of tracking antimicrobial use and resistance patterns across sectors achieved more rapid identification of emerging resistance threats and demonstrated more effective targeted interventions.

Discussion

These findings provide essential insights into the temporal dynamics and structural requirements of effective AMR governance, with direct implications for clinical practice and healthcare policy development. The five-year delay between policy implementation and measurable AMR outcomes represents a critical consideration for healthcare administrators and infectious disease specialists evaluating intervention effectiveness.

The superior performance of countries with integrated multisector governance structures aligns with established principles of One Health implementation, though the magnitude of the effect sizes provides new quantitative evidence for policy prioritization decisions. The strong association between surveillance infrastructure and improved outcomes underscores the fundamental importance of data-driven decision making in AMR management.

For healthcare systems serving diverse populations, including Pacific Islander communities in Hawaii, these findings emphasize the importance of sustained policy commitment and adequate resource allocation for surveillance infrastructure. The Hawaii Department of Health’s AMR monitoring capabilities and coordination with institutions such as the John A. Burns School of Medicine (JABSOM) represent critical components of effective regional governance structures.

The observed disparities between human health governance and animal/environmental health capabilities highlight a persistent implementation gap. This finding has particular relevance for Hawaii’s healthcare system, given the state’s significant agricultural sector and unique environmental characteristics that may influence resistance gene dissemination patterns.

Limitations

Several important limitations constrain the interpretation of these findings. The reliance on policy documents and survey data may not fully capture implementation quality or real-world governance effectiveness. Surveillance data availability varies substantially between countries, potentially introducing systematic bias in outcome assessments. The five-year observation period, while sufficient to detect policy impacts, may be inadequate to characterize long-term sustainability of governance improvements.

The governance index, despite expert validation, represents a composite measure that may not fully capture country-specific contextual factors influencing AMR dynamics. Additionally, the analysis cannot fully account for concurrent interventions or policy changes that may have influenced AMR outcomes independent of formal NAP implementation.

Clinical Implications

These findings have immediate relevance for clinical practice and healthcare policy development across multiple domains. Infectious disease specialists and hospital epidemiologists should anticipate delayed responses to institutional AMR interventions, with meaningful outcome measures potentially requiring five-year evaluation periods for adequate assessment.

The demonstrated importance of multisector engagement suggests that clinical AMR stewardship programs should incorporate veterinary and environmental health perspectives, particularly in regions with significant agricultural activity or unique environmental characteristics such as Hawaii’s island ecosystems. Hospital-based stewardship programs should establish formal coordination mechanisms with public health authorities, veterinary professionals, and environmental monitoring systems.

For healthcare administrators, the findings emphasize the critical importance of sustained investment in surveillance infrastructure. Electronic health record systems should incorporate enhanced AMR tracking capabilities, and laboratory information systems require integration with broader surveillance networks to support evidence-based decision making.

Clinical decision-making processes should incorporate awareness of the temporal dynamics demonstrated in this analysis. Antimicrobial prescribing guidelines and institutional policies require regular reassessment using extended evaluation periods to capture the full impact of interventions. This has particular importance for remote healthcare systems such as those serving Pacific Islander populations, where resistance pattern changes may follow different temporal trajectories due to geographic isolation and distinct transmission dynamics.

The analysis also supports enhanced coordination between clinical microbiology laboratories and public health surveillance systems. Laboratory-based surveillance capabilities require integration with national and international monitoring networks to support rapid identification of emerging resistance threats and facilitate coordinated response efforts.

References

1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0

2. Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0

3. World Health Organization. Global Action Plan on Antimicrobial Resistance. Geneva: World Health Organization; 2015.

4. Evaluation of antimicrobial resistance governance across 193 countries to inform the 2026 Global Action Plan update. Nat Med. 2026. doi:10.1038/s41591-026-04257-1

5. Rochford C, Sridhar D, Woods N, et al. Global governance of antimicrobial resistance. Lancet. 2018;391(10134):1976-1978. doi:10.1016/S0140-6736(18)31117-6

6. Mendelson M, Røttingen JA, Gopinathan U, et al. Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries. Lancet. 2016;387(10014):188-198. doi:10.1016/S0140-6736(15)00547-4